HBOT and Cancer: Why Timing Matters More Than Almost Anything Else

Few topics in hyperbaric medicine require more careful handling than the relationship between HBOT and cancer. The question is not simply whether HBOT is safe for cancer patients. It is a question of timing, biological context, and the fundamental difference between a body that is actively fighting a malignancy and one that has achieved sustained remission.

The short answer is this: HBOT is contraindicated during active cancer treatment, and that contraindication is grounded in serious biological reasoning. For patients in sustained remission, typically defined as six months or more without evidence of disease, the picture changes considerably, and HBOT may offer meaningful support for the long-term effects of cancer treatment. But the distinction between these two states is not a technicality. It is clinically essential.

This article explains why.

The Biological Concern During Active Treatment

To understand why HBOT is contraindicated during active cancer treatment, it helps to understand what HBOT does at a cellular level, and why those effects are precisely what you do not want in the presence of an active malignancy.

Oxygen and Tumour Growth

Cancer cells, like all cells, require oxygen to survive and proliferate. Many solid tumours develop regions of hypoxia, low oxygen tension, as they outgrow their blood supply. This hypoxic microenvironment is actually a double-edged sword for the tumour. On one hand, it creates metabolic stress that can slow tumour growth. On the other hand, hypoxia activates a range of adaptive responses in cancer cells that make them more aggressive, more resistant to treatment, and more likely to metastasise.

The concern with HBOT during active cancer treatment is that by dramatically increasing tissue oxygen tension, it may relieve the hypoxic stress that is partially constraining tumour growth, and in doing so, provide the metabolic substrate for accelerated tumour proliferation. The theoretical risk is that HBOT could fuel the very process it is being asked to help with.

This concern is not merely theoretical. Laboratory studies have demonstrated that elevated oxygen tension can stimulate the growth of certain cancer cell lines in vitro. The clinical significance of these findings in human patients is less clear, and the evidence is not uniformly negative, but the precautionary principle applies with considerable force when the stakes are this high.

Angiogenesis and Tumour Vascularisation

HBOT stimulates angiogenesis, the growth of new blood vessels, through upregulation of vascular endothelial growth factor (VEGF) and other pro-angiogenic signalling pathways. In the context of wound healing, surgical recovery, and neurological repair, this is one of HBOT's most therapeutically valuable properties.

In the context of an active tumour, it is a significant concern. Tumour angiogenesis, the development of a new blood supply to feed a growing malignancy, is one of the key mechanisms by which cancers grow, invade surrounding tissue, and ultimately metastasise. Stimulating angiogenesis in a patient with active cancer risks providing the tumour with the vascular infrastructure it needs to expand.

Anti-angiogenic therapies, drugs that specifically block VEGF signalling to starve tumours of their blood supply, are among the most important advances in oncology over the past two decades. Using HBOT, which stimulates the same VEGF pathways that anti-angiogenic drugs are designed to block, during active cancer treatment would work directly against the mechanism of some of the most effective treatments available.

Interaction with Chemotherapy and Radiotherapy

The interaction between HBOT and active cancer treatment is not limited to the direct effects on tumour biology. There are also concerns about how HBOT interacts with specific chemotherapy agents and with radiotherapy.

Certain chemotherapy drugs, including bleomycin and doxorubicin, have known pulmonary and cardiac toxicities that may be exacerbated by high oxygen concentrations. Patients receiving these agents should not undergo HBOT, and the contraindication persists for a period after treatment ends, as the drugs can remain in tissues and their toxicity can be potentiated by oxygen exposure.

The interaction with radiotherapy is more nuanced. HBOT has an established role in treating the late effects of radiotherapy, including osteoradionecrosis and soft tissue radionecrosis, and there is research interest in using HBOT as a radiosensitiser to enhance the effectiveness of radiotherapy in hypoxic tumours. But this is a highly specialised application conducted under strict oncological supervision, not a general use of HBOT during cancer treatment. Outside of these specific research protocols, HBOT during active radiotherapy is not appropriate without explicit oncological oversight.

The Position of Medical Authorities

The Undersea and Hyperbaric Medical Society (UHMS), the primary professional body governing hyperbaric medicine, lists untreated malignancy as a relative contraindication to HBOT. The word relative is important here. It means that the contraindication is not absolute in every conceivable clinical scenario, and that there are specific, supervised research contexts in which HBOT is being studied alongside cancer treatment. But for the overwhelming majority of patients undergoing active cancer treatment outside of a formal research protocol, HBOT is not appropriate, and any reputable hyperbaric facility will decline to treat them.

The clinical decisions about whether HBOT is appropriate during any phase of cancer treatment belong exclusively to the treating oncologist. This is not a decision that a hyperbaric facility should make independently, and it is not a decision that a patient should make without explicit guidance from their oncology team.

After Remission: A Different Biological Context

Sustained remission changes the biological context in ways that are clinically meaningful. When a patient has been free of detectable disease for six months or more, the concerns about fuelling tumour growth and stimulating tumour angiogenesis are substantially reduced, though not entirely eliminated. The body is no longer in a state of active malignancy, and the physiological effects of HBOT can be considered in a different light.

The six-month threshold is not arbitrary. It reflects the period over which the risk of early relapse is highest, and after which the probability of sustained disease-free status increases meaningfully. It also allows time for the acute effects of chemotherapy and radiotherapy to resolve, reducing the risk of drug interactions and treatment-related toxicity.

For patients in sustained remission, HBOT may offer support in several important areas.

Radiation Injury and Late Effects

The late effects of radiotherapy are among the most significant long-term consequences of cancer treatment, and they represent the most evidence-supported application of HBOT in the post-cancer context.

Radiation causes progressive obliterative endarteritis in the tissues it passes through, a process in which the small blood vessels are progressively destroyed over months and years following treatment. The result is chronically hypoxic, poorly vascularised tissue that is vulnerable to breakdown, infection, and failure to heal following any subsequent injury or surgical intervention.

Osteoradionecrosis, the death of bone in a previously irradiated field, is an established UHMS indication for HBOT. It most commonly affects the jaw following head and neck radiotherapy, but can occur in any bone that has received significant radiation dose. HBOT promotes angiogenesis in the irradiated tissue, improving its vascularity and creating conditions in which the bone can heal.

Soft tissue radionecrosis, the equivalent process in soft tissue, is also an established UHMS indication. Patients who develop non-healing wounds, fistulae, or tissue breakdown in previously irradiated fields are candidates for HBOT, provided they are in sustained remission and their oncology team has confirmed that the tissue changes are attributable to radiation injury rather than recurrent disease.

Radiation cystitis and radiation proctitis, inflammatory conditions of the bladder and rectum following pelvic radiotherapy, are further established indications. These conditions can cause significant long-term morbidity, including bleeding, pain, and impaired organ function, and HBOT has demonstrated consistent benefit in reducing symptoms and promoting tissue healing in this context.

Chemotherapy-Related Cognitive Effects

Cognitive impairment following chemotherapy, sometimes referred to informally as chemotherapy-related cognitive impairment, is a recognised and often underacknowledged consequence of cancer treatment. Patients describe difficulties with memory, concentration, processing speed, and executive function that can persist for months or years after treatment ends.

The neurobiological mechanisms underlying this condition include neuroinflammation, oxidative stress, and reduced cerebral blood flow, all of which are within the therapeutic target of HBOT. Research into HBOT for chemotherapy-related cognitive impairment is at an early stage, but the mechanistic rationale is coherent, and there is growing clinical interest in this application.

A 2020 study published in the journal Integrative Cancer Therapies examined HBOT in breast cancer survivors with persistent cognitive impairment following chemotherapy. Participants received 40 sessions of HBOT and demonstrated improvements in cognitive function, quality of life, and cerebral blood flow on imaging. The study was small and uncontrolled, but the findings are consistent with the known mechanisms of HBOT and support further investigation.

Fatigue and Quality of Life

Cancer-related fatigue is one of the most prevalent and debilitating long-term effects of cancer treatment. It is distinct from ordinary tiredness and does not resolve with rest. Its mechanisms are multifactorial, involving mitochondrial dysfunction, neuroinflammation, hypothalamic-pituitary-adrenal axis dysregulation, and persistent immune activation.

HBOT's effects on mitochondrial function, through increased oxygen availability and stimulation of mitochondrial biogenesis, and its anti-inflammatory properties make it a mechanistically plausible intervention for cancer-related fatigue. Clinical evidence in this area is limited but growing, and several cancer survivorship programmes have incorporated HBOT as part of a broader approach to managing long-term treatment effects.

Peripheral Neuropathy

Chemotherapy-induced peripheral neuropathy, characterised by numbness, tingling, pain, and weakness in the hands and feet, is a common and often persistent consequence of certain chemotherapy agents, including platinum-based drugs, taxanes, and vinca alkaloids. It results from damage to peripheral nerve axons and the myelin sheaths that surround them.

HBOT's capacity to promote neuroplasticity, reduce neuroinflammation, and improve oxygen delivery to hypoxic peripheral nerve tissue makes it a candidate intervention for chemotherapy-induced peripheral neuropathy. Research in this area is at an early stage, but case series and small prospective studies have reported improvements in neuropathy symptoms following HBOT in cancer survivors.

What Patients in Remission Should Understand

For patients who have completed cancer treatment and achieved sustained remission, HBOT is not a decision to make independently or in isolation from their oncology team. The following principles apply.

The treating oncologist must be involved in any decision to pursue HBOT. This is not a formality. The oncologist needs to confirm that the patient is genuinely in sustained remission, that there is no evidence of residual or recurrent disease, and that the specific chemotherapy agents used do not create ongoing contraindications to high-pressure oxygen exposure. Some agents, particularly bleomycin, carry contraindications that persist beyond the end of treatment.

The hyperbaric facility must be informed of the full oncological history. A reputable facility will require this information before accepting a patient with a cancer history, and will seek confirmation from the oncology team before proceeding. Any facility that does not ask about cancer history or that treats patients with active or recent malignancy without oncological oversight is not operating to an appropriate standard of care.

The indication for HBOT should be clearly defined. For patients in remission, the most evidence-supported indications are the late effects of radiotherapy, including osteoradionecrosis, soft tissue radionecrosis, and radiation cystitis. For other applications, including cognitive impairment, fatigue, and peripheral neuropathy, the evidence is more limited and the decision to pursue HBOT should be made with realistic expectations about what the research currently supports.

The Honest Position

HBOT is contraindicated during active cancer treatment for serious biological reasons, and those reasons should be respected without exception outside of formal research protocols conducted under oncological supervision.

For patients in sustained remission, HBOT may offer meaningful support for the long-term effects of cancer treatment, particularly radiation injury. The evidence for these applications is well established in some areas and emerging in others.

The line between these two states, active treatment and sustained remission, is not always clean in clinical practice. Patients with complex treatment histories, ongoing surveillance, or borderline disease status require careful individual assessment. That assessment belongs to the oncologist, in collaboration with the hyperbaric physician, and it is not a decision that should be made by the patient alone or by a hyperbaric facility acting without oncological input.

For anyone navigating this question, whether as a patient, a family member, or a clinician, understanding the biological basis for both the contraindication and the post-remission opportunity is the right starting point.